29th Annual Cancer Progress Conference
May 8-9, 2018
Convene at 32 Old Slip, NYC

Tuesday, May 8, 2018

7:00 – 8:00am  Registration and Continental Breakfast

8:00 – 8:15am  Opening Remarks

Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health

8:15 – 9:15am  Keynote:
Laura Esserman, MD, MBA, Director, UCSF Carol Franc Buck Breast Cancer Center; Alfred A. de Lorimier Endowed Chair in General Surgery; Professor of Surgery and Radiology, UCSF

9:15 – 10:30am  Cell Therapies as the New Space Race: Engineering Generation X.0

Moderator: Mike Rice, MS, MBA, Principal, Defined Health

Panelists:
- Renier Brentjens, MD, PhD, Medical Oncologists; Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
- Nouhad Husseini, Head of Business Development, Regeneron Pharmaceuticals, Inc.
- Stanley Frankel, MD, Corporate Vice President, Global Clinical R&D Hematology/Oncology, Celgene
- Julianne Smith, PhD, Vice President, Translational Sciences, Cellectis
- Pascal Touchon, Senior Vice President & Global Head, Cell & Gene therapy, Novartis Oncology

10:30 – 11:00am  Networking Break

11:00 – 12:15pm  Oncology Diagnostics – Reading the Future

Moderator: Joel Sandler, PhD, Associate Principal, Defined Health

Panelists:
- Sharon Benzeno, PhD, MBA, Senior Vice President, Research and Business Development, Adaptive Biotechnologies
- Ken Bloom, MD, President, Human Longevity
- Lisa H. Butterfield, PhD, Professor of Medicine, Surgery, Immunology and Clinical and Translational Science; Director, Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, UPMC Hillman Cancer Center
- Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString
- Leora Schiff, MS, MBA, Principal, Altius Strategy Consulting, LLC

12:15 – 1:30pm  Networking Luncheon
1:30 – 2:45pm  Progress in Intractable Cancers- Part I – Heme Malignancies

Moderator: Mike Rice, MS, MBA, Principal, Defined Health

Panelists:
- Kenneth Anderson, MD, Kraft Family Professor of Medicine, Harvard Medical School
- Stanley Frankel, MD, Corporate Vice President, Global Clinical R&D Hematology/Oncology, Celgene
- William Matsui, MD, Professor of Oncology, Johns Hopkins

2:45 – 4:00pm  Innovative Trials & Collaborative Initiatives – Role of Patient Advocacy, Foundations & Institutes

Moderator: Jeremy Goldberg, President, JPG Healthcare LLC

Panelists:
- Lou DeGennaro, PhD, President and Chief Executive Officer, The Leukemia & Lymphoma Society
- Lorraine Egan, President and Chief Executive Officer, Damon Runyon
- Ramy Ibrahim, MD, Vice President, Clinical Research & Development, Parker Institute
- T.J. Sharpe, Patient Writer, Speaker, & Patient Experience Advisor, Starfish Harbor, LLC

4:00 – 4:15pm  Networking Break

4:15 – 5:30pm  Value & Pricing Redux – Does the Song Remain the Same?

Moderator: Ed Saltzman, Executive Chairman, Defined Health

Panelists:
- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Daniel Becker, MD, MS, Section Chief, Hematology and Oncology, VA-NYHHS; Assistant Clinical Professor of Medicine, New York University School of Medicine
- Kapil Dhingra, MD, Managing Member, KAPital Consulting
- Roger Longman, Chief Executive Officer, Real Endpoints

5:30 – 7:30pm  Cancer Progress 2018 Reception

Wednesday, May 9, 2018

7:00 – 8:00am  Registration and Continental Breakfast

8:00 – 8:15am  Opening Remarks: Review of Day 1

Mike Rice, MS, MBA, Principal, Defined Health
**8:15 – 9:30 am**  
Advances in Intractable Cancers - Part II – Solid Tumors  
Moderator: James Lee, PhD, Associate Principal, Oncology Lead, Defined Health  
Panelists:  
- Michael Tomblyn, MD, MS, Head of US Development & US Medical Director, Nanobiotix  
- David Tuveson, MD, PhD, Professor; Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL; Director of Research for the Lustgarten Foundation  
- Denise Reinke, MS, NP, MBA, President and Chief Executive Officer, SARC  
- Wendy K.D. Selig, Founder and Chief Executive Officer, WSCollaborative, LLC

**9:30 – 10:00am**  
Networking Break

**10:00 – 11:15am**  
Innate & Adaptive Resistance to IO – Is It the TME’s Time to Shine?  
Moderator: Mark Simon, Managing Director, Torreya  
Panelists:  
- Tom Gajewski, MD, PhD, Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine- Section of Hematology/Oncology, University of Chicago  
- Sumayah Jamal, MD, PhD, President, Co-Founder and Chief Scientific Officer, ENB Therapeutics  
- Llew Keltner, MD, PhD, Chief Executive Officer, Epistat  
- Timothy Reilly, PhD, DABT, Vice President, Head of Oncology Early Asset Development, Bristol-Myers Squibb  
- Dmitriy Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center

**11:15 – 12:30**  
Next Wave Antibodies and Biologics: Is IO Poised for a Sea of Change?  
Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health  
Panelists:  
- Mike Curran, PhD, Assistant Professor, The University of Texas, MD Anderson Cancer Center  
- John Haurum, MD, DPhil, Chief Executive Officer, F-Star  
- Louis Matis, MD, Chief Development Officer, Pieris Pharmaceuticals  
- Carsten Reinhardt, MD, PhD, Chief Medical Officer, Immatics  
- Taylor Schreiber, MD, PhD, Chief Scientific Officer, Shattuck Labs, Inc.

**12:30 – 1:45pm**  
Networking Lunch

**1:45 – 3:00 pm**  
Point-Counterpoint: Cancer Progress, at the Crossroads or at a Tipping Point?  
Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health
Panelists:
- Axel Hoos, MD, PhD, Senior Vice President, Therapeutic Area Head R&D, GlaxoSmithKline
- Christoph Lengauer, PhD, Venture Partner, Third Rock Ventures
- Brian Leyland-Jones, MBBS, PhD, Vice President, Avera Cancer Institute Center for Precision Oncology and Department of Molecular and Experimental Medicine, Avera Cancer Institute
- Peter Sandor, MD, MBA, Vice President, Head of Oncology Therapeutic Area Marketing, Astellas Pharma US, Inc.

3:00 pm Cancer Progress 2018 Conference Concludes